ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984

Kidney, Bladder Cancer Causes, Treatment, Need More Research, NCI Advisors Find

July 26, 2002

In Brief: NIH gives Advisors $50 Raise, Effective April 1, No Fooling

March 12, 1999

New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance

July 27, 1984

Radiotherapy Plus Cetuximab May Control Head/Neck Cancer

November 26, 2010

In Brief: Cancer Act Renewal Hearings Completed ; Administration Stays With Objections To More Centers, Specific Budget Figures

February 22, 1974